ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1920

Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins

Laurence S Magder1, Eric Zollars2, Jadwiga Bienkowska3, Chris Stebbins4, Carrie Wager5, Linda Burkly6, Nicolas Wisniacki7, Ann Ranger8 and Michelle Petri9, 1Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD, 2Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3Translational Medicine, Biogen Idec Inc., Cambridge, MA, 4Translational Medicine, Biogen Idec, Cambridge, MA, 5Biostatistics, Biogen Idec, Cambridge, MA, 6Biogen Idec, Cambridge, MA, 7Formerly with Biogen Idec, Cambridge, MA, 814 Cambridge Center, Biogen Idec, Cambridge, MA, 9Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: biomarkers and longitudinal studies, Disease Activity, Gene Expression, SLE

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus

Session Type: Abstract Submissions (ACR)

Background/Purpose

Multiple gene transcripts and proteins in blood or urine have been observed to correlate with disease activity in SLE. However some observed associations might be spurious, due to confounding by correlation with other biomarkers or patient characteristics.  In this study, we explored the relationship between six proposed biomarkers and SLE activity over a 1 year period while controlling for potential confounding variables. 

Methods

At an initial visit, two proteins and four gene transcripts or signatures were measured in 280 SLE patients. Levels of the BAFF gene transcript, plasma cell (PC) gene signature, IFN gene signature, and an LDG-associated Neutrophil gene signature were assessed in PAXgene-preserved peripheral blood by global microarray and qPCR. For proteins, BAFF was measured in serum and TWEAK in urine (both by ELISA). Disease activity during the next year was quantified by SELENA-SLEDAI modified to exclude complement and dsDNA. Repeated measures linear regression models were fit to determine which markers were predictive of disease activity over a one year period, controlling for age, race, sex, and other markers. Non-linear relationships between biomarker levels and disease activity were also explored.

Results

In univariate analyses, all markers analyzed except BAFF protein were significantly associated with future disease activity. After controlling for race, the PC signature was no longer significantly associated. After controlling for BAFF mRNA levels, the IFN signature was no longer significantly associated. Controlling for sex, race, and other biomarkers we found that: 1) a 1 standard deviation (SD) increase in BAFF was associated with a mean SLEDAI increase of 0.26 in the follow-up (p=0.0034), 2) those patients within the top 15% of the Neutrophil gene signature expression had a 0.66 higher mean SLEDAI during follow-up (p=0.0056), and 3) the relationship between the SLEDAI score and urinary TWEAK protein was constant until the 85th percentile of TWEAK after which a 1 SD increase in TWEAK was associated with a 0.58 increase in mean SLEDAI (p=0.0006). In a similar analysis focusing on renal disease activity, a 1 SD increase in the IFN signature was associated with a mean renal SLEDAI increase of 0.11 (p=0.04). The Neutrophil signature remained significant at a similar level as for overall disease activity, and the relationship between renal SLEDAI score and urinary TWEAK was linear with a 1 SD increase in TWEAK being associated with a 0.25 increase in mean renal SLEDAI (p<0.0001).

Conclusion

BAFF gene transcript, LDG-associated neutrophil gene signature, and high levels of urinary TWEAK appear to be independently and additively associated with disease activity.  Our results suggest that the association between IFN and overall disease activity is due to the association between IFN and BAFF. Our results also suggest that an observed association between PC and disease activity is due to confounding by race. Thus, given that biomarkers are correlated with each other and other risk factors for disease, it is important to adjust for confounding when assessing biomarker/disease relationships.


Disclosure:

L. S. Magder,
None;

E. Zollars,

Biogen Idec,

2;

J. Bienkowska,

Biogen Idec,

3,

Biogen Idec,

1;

C. Stebbins,

Biogen Idec,

3;

C. Wager,

Biogen Idec,

3,

Biogen Idec,

1;

L. Burkly,

Biogen Idec,

2;

N. Wisniacki,

Biogen Idec,

3;

A. Ranger,

Biogen Idec,

3;

M. Petri,

Biogen Idec,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-sle-disease-activity-in-the-next-year-based-on-measures-of-four-gene-transcripts-and-two-proteins/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology